EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mega Lifesciences PCL's enterprise value is ฿30,951.39 Mil.
Mega Lifesciences PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ฿2,597.23 Mil. Therefore, Mega Lifesciences PCL's EV-to-EBITDA for today is 11.92.
The historical rank and industry rank for Mega Lifesciences PCL's EV-to-EBITDA or its related term are showing as below:
BKK:MEGA-F'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.94 Med: 16.85 Max: 28.02
Current: 12.36
During the past 13 years, the highest EV-to-EBITDA of Mega Lifesciences PCL was 28.02. The lowest was 10.94. And the median was 16.85.
BKK:MEGA-F's EV-to-EBITDA is ranked better than 57.34% of 715
companies
in the Drug Manufacturers industry
Industry Median: 14.5
vs BKK:MEGA-F: 12.36
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Mega Lifesciences PCL EV-to-EBITDA Historical Data
The historical data trend for Mega Lifesciences PCL's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mega Lifesciences PCL's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Mega Lifesciences PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mega Lifesciences PCL's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mega Lifesciences PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mega Lifesciences PCL's EV-to-EBITDA falls into.
Mega Lifesciences PCL's current Enterprise Value is ฿30,951.39 Mil.
Mega Lifesciences PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿2,597.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mega Lifesciences PCL (BKK:MEGA-F) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mega Lifesciences PCL's PE Ratio for today is calculated as:
Mega Lifesciences PCL's share price for today is ฿0.00.
Mega Lifesciences PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Mega Lifesciences PCL's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Mega Lifesciences PCL (BKK:MEGA-F) Business Description
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins and fast-moving consumer goods as well as the provides distribution services relating to such products. The company's products portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins and fast moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purpose and sale of goods manufactured by third parties; and OEM.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BKK:MEGA-F has been successfully added to your 